ArticleJournal of neuroscience research2009
Involvement of calpain in the process of Jurkat T cell chemotaxis.
Article in Journal of neuroscience research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- A cysteine proteinase inhibitor ALLN alleviates bleomycin-induced skin and lung fibrosis.Arthritis research & therapy · 2023Article
- Protective effect of calpain inhibitors against manganese-induced toxicity in rats.Metabolic brain disease · 2022Article
- Cell-Permeable Calpain Inhibitor SJA6017 Provides Functional Protection to Spinal Motoneurons Exposed to MPPNeurotoxicity research · 2020Article
- Calpain mediated expansion of CD4+ cytotoxic T cells in rodent models of Parkinson's disease.Experimental neurology · 2020Article
- Chemotactic Responses of Jurkat Cells in Microfluidic Flow-Free Gradient Chambers.Micromachines · 2020Article
- Calpain inhibition as a possible new therapeutic target in multiple sclerosis.AIMS molecular science · 2017Article
- Calpain inhibition reduces structural and functional impairment of retinal ganglion cells in experimental optic neuritis.Journal of neurochemistry · 2016Article
- Rapid assay of stem cell functionality and potency using electric cell-substrate impedance sensing.Stem cell research & therapy · 2015Article
- Inhibition of Calpain Activation Protects MPTP-Induced Nigral and Spinal Cord Neurodegeneration, Reduces Inflammation, and Improves Gait Dynamics in Mice.Molecular neurobiology · 2015Article
- Opportunistic pathogen Candida albicans elicits a temporal response in primary human mast cells.Scientific reports · 2015Article
- CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12.PloS one · 2014Article
- Critical role of calpain in spinal cord degeneration in Parkinson's disease.Journal of neurochemistry · 2013Article
- Myelin recovery in multiple sclerosis: the challenge of remyelination.Brain sciences · 2013Article
- The Involvement of Calpain in CD4Journal of clinical & cellular immunology · 2013Article
- Calpain inhibition protected spinal cord motoneurons against 1-methyl-4-phenylpyridinium ion and rotenone.Neuroscience · 2011Article
- Calpeptin attenuated apoptosis and intracellular inflammatory changes in muscle cells.Journal of neuroscience research · 2011Article
- Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients.Journal of neuroimmunology · 2011Article
- Article
- Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis.Journal of neuroscience research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Massive T cell infiltration into the central nervous system is a hallmark of multiple sclerosis (MS) and its rodent model experimental autoimmune encephalomyelitis (EAE), resulting in the induction of many of the pathophysiological events that lead to neuroinflammation and neurodegeneration. Thus, blocking T cell migration into the central nervous system may reduce disease severity in MS and EAE. One potential target for reducing T cell migration is inhibition of the Ca(2+)-activated neutral protease calpain. Previous studies in other cell types have demonstrated that migration is reduced by incubation of cells with calpain inhibitors. Thus, we hypothesize that calpain inhibition will reduce migration of T cells in response to and toward the chemokine CCL2. To test this hypothesis, the intracellular free Ca(2+) levels in Jurkat E6-1 T cells was first measured by the fura-2 assay to assess whether the intracellular ion environment would support calpain activation. The intracellular free Ca(2+) levels were found to increase in response to CCL2. The cells were next treated with the calpain inhibitor calpeptin in a multiwelled Boyden chamber with CCL2 used as the chemoattractant. These studies demonstrate that inhibition of calpain with its inhibitor calpeptin produces a dose-dependent inhibition of chemotaxis. Calpain activity, as measured by live cell imaging, was also increased in response to CCL2, providing further evidence of its involvement in the process of chemotaxis and migration. These studies provide evidence for the involvement of calpain in the mechanisms of chemotaxis and warrants further exploration in MS patient and EAE animal samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.